Linked Life Data

20658263

Source:http://linkedlifedata.com/resource/pubmed/id/20658263

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20658263rdf:typepubmed:Citationlld:pubmed
pubmed-article:20658263lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:20658263lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20658263lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:20658263lifeskim:mentionsumls-concept:C0010583lld:lifeskim
pubmed-article:20658263lifeskim:mentionsumls-concept:C0144576lld:lifeskim
pubmed-article:20658263lifeskim:mentionsumls-concept:C0728747lld:lifeskim
pubmed-article:20658263lifeskim:mentionsumls-concept:C0031928lld:lifeskim
pubmed-article:20658263lifeskim:mentionsumls-concept:C1450054lld:lifeskim
pubmed-article:20658263lifeskim:mentionsumls-concept:C1522673lld:lifeskim
pubmed-article:20658263pubmed:issue2lld:pubmed
pubmed-article:20658263pubmed:dateCreated2010-8-11lld:pubmed
pubmed-article:20658263pubmed:abstractTextnab-Paclitaxel has shown favorable efficacy and toxicity profiles compared to other taxanes in the treatment of metastatic breast cancer. In this pilot trial, we evaluated a nab-paclitaxel-containing adjuvant regimen in patients with early stage breast cancer. Patients with node-positive or high-risk node-negative early-stage breast cancer were eligible following completion of standard primary therapy. All the patients received four cycles, at 21-day intervals, of nab-paclitaxel (100 mg/m(2) IV days 1, 8, and 15) and cyclophosphamide (600 mg/m(2) IV day 1). HER2-positive patients also received trastuzumab 8 mg/kg IV on cycle 1 day 1, followed by 6 mg/kg every 21 days for a total of 52 weeks. The purpose of this trial was to evaluate feasibility and toxicity of this nab-paclitaxel-containing adjuvant regimen. 62 patients were treated between 2/08 and 11/08. The majority of the patients (87%) were HER2-negative. This adjuvant regimen was well tolerated, and full doses of all agents were administered in >90% of cycles. Grade 3/4 neutropenia occurred in 53% of the patients; however, only one episode of febrile neutropenia occurred in a total of 249 cycles administered. Other grade 3/4 adverse events occurred in less than 5% of patients. After short follow-up, all the patients remain alive and disease-free. The combination of nab-paclitaxel and cyclophosphamide, with or without trastuzumab, is feasible and well tolerated in patients with early stage breast cancer. Further investigation of the role of nab-paclitaxel in adjuvant breast cancer therapy is indicated, but definitive evaluation will require randomized phase III trials.lld:pubmed
pubmed-article:20658263pubmed:languageenglld:pubmed
pubmed-article:20658263pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20658263pubmed:citationSubsetIMlld:pubmed
pubmed-article:20658263pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20658263pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20658263pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20658263pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20658263pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20658263pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20658263pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20658263pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20658263pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20658263pubmed:statusMEDLINElld:pubmed
pubmed-article:20658263pubmed:monthSeplld:pubmed
pubmed-article:20658263pubmed:issn1573-7217lld:pubmed
pubmed-article:20658263pubmed:authorpubmed-author:HainsworthJoh...lld:pubmed
pubmed-article:20658263pubmed:authorpubmed-author:RaefskyEricElld:pubmed
pubmed-article:20658263pubmed:authorpubmed-author:YardleyDenise...lld:pubmed
pubmed-article:20658263pubmed:authorpubmed-author:BurrisHowardH...lld:pubmed
pubmed-article:20658263pubmed:authorpubmed-author:ShipleyDianna...lld:pubmed
pubmed-article:20658263pubmed:authorpubmed-author:PeacockNancyNlld:pubmed
pubmed-article:20658263pubmed:authorpubmed-author:MelnikMariann...lld:pubmed
pubmed-article:20658263pubmed:authorpubmed-author:InhornRogerRlld:pubmed
pubmed-article:20658263pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20658263pubmed:volume123lld:pubmed
pubmed-article:20658263pubmed:ownerNLMlld:pubmed
pubmed-article:20658263pubmed:authorsCompleteYlld:pubmed
pubmed-article:20658263pubmed:pagination471-5lld:pubmed
pubmed-article:20658263pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:meshHeadingpubmed-meshheading:20658263...lld:pubmed
pubmed-article:20658263pubmed:year2010lld:pubmed
pubmed-article:20658263pubmed:articleTitleA pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.lld:pubmed
pubmed-article:20658263pubmed:affiliationSarah Cannon Research Institute, 3322 West End Avenue Suite 900, Nashville, TN 37203, USA.lld:pubmed
pubmed-article:20658263pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20658263pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:20658263pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:20658263pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
entrez-gene:2064entrezgene:pubmedpubmed-article:20658263lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:20658263lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20658263lld:pubmed